Literature DB >> 19141118

More than a third of non-gastric malt lymphomas are disseminated at diagnosis: a single center survey.

Mirjana Sretenovic1, Milica Colovic, Gradimir Jankovic, Nada Suvajdzic, Biljana Mihaljevic, Natasa Colovic, Milena Todorovic, Henry Dushan E Atkinson.   

Abstract

Mucosa-associated lymphoid tissue (MALT) lymphomas are extranodal B-cell tumors that generally follow an indolent course. The gastrointestinal tract is the most common site of MALT lymphoma, comprising 50% of all cases. The tissue lesions are often localized, have high therapeutic response rates with late relapses with a long overall survival (OS). The patients with non-gastric lesions may follow a different clinical course and many of them present with disseminated disease. This study reports a series of 51 patients with non-gastric MALT lymphoma. Twenty patients (39.2%) presented with disseminated disease, seven (13.7%) patients had two MALT mucosal sites involved and eight (15.7%) had involvement of three or more mucosal sites. At presentation, 17 (33.3%) patients had the lymph node and 12 (23.5%) the bone marrow involvement. Following various combinations of treatment, complete remission was achieved in 40 (81.6%), and partial remission in three of the 49 treated patients with no difference in response rates between different disease stages. Relapse occurred in 12/43 (27.9%) patients among whom eight (18.6%) recurred in the presenting organ system. Five patients (9.8%) died because of a rapid disease progression after a median follow-up of 56 months; two patients with primary lung lesions, 1 patient with secondary intestinal disease, and 2 patients suffered transformation to diffuse large B-cell lymphoma. No significant difference in survival was found between localized and disseminated disease (log rank 0.05, df = 1, P = 0.81). A patient age > or = 60 yr at diagnosis and presentation with the nodal disease were found to be statistically significant negative prognostic factors (P < 0.05). Median OS was not reached after 145 months of follow-up, with the estimated OS being 88% at 2 yr, and 78% at 5 yr.

Entities:  

Mesh:

Year:  2009        PMID: 19141118     DOI: 10.1111/j.1600-0609.2009.01217.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  6 in total

1.  Primary ocular adnexal mucosa-associated lymphoid tissue lymphoma (MALT): single institution experience in a large cohort of patients.

Authors:  Soley Bayraktar; Ulas D Bayraktar; Alexandra Stefanovic; Izidore S Lossos
Journal:  Br J Haematol       Date:  2010-11-18       Impact factor: 6.998

2.  Disseminated Gastric MALT Lymphoma with Monoclonal Gammopathy, t(11;18)(q21;q21), and Subsequent Development of T-Large Granular Lymphocytic Leukemia: A Case Report and Review of the Literature.

Authors:  Riad Akoum; Wassim Serhal; Hussein Farhat
Journal:  Case Rep Med       Date:  2015-05-06

3.  CT, MRI, and 18F-FDG PET/CT Findings in Untreated Pulmonary and Hepatic B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) Over a Five-Year Period: A Case Report.

Authors:  Aisheng Dong; Zhengguang Xiao; Jianmin Yang; Changjing Zuo
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

Review 4.  Novel developments in the pathogenesis and diagnosis of extranodal marginal zone lymphoma.

Authors:  Max I Schreuder; Michiel van den Brand; Konnie M Hebeda; Patricia J T A Groenen; J Han van Krieken; Blanca Scheijen
Journal:  J Hematop       Date:  2017-09-25       Impact factor: 0.196

5.  Comparison of Selection and Long-term Clinical Outcomes Between Chemotherapy and Radiotherapy as Primary Therapeutic Modality for Ocular Adnexal MALT Lymphoma.

Authors:  Young-Woo Jeon; Hee-Jung Yang; Byung-Ock Choi; Seung-Eun Jung; Kyung-Sin Park; Joo-Hyun O; Suk-Woo Yang; Seok-Goo Cho
Journal:  EClinicalMedicine       Date:  2018-10-17

6.  Right Middle Lobe Single Pulmonary Opacity With Air Bronchogram: A Problem-Solving Case Report.

Authors:  Sara Khademolhosseini; Seyedmohammad Pourshahid; Milana Zirkiyeva; Theo Trandafirescu
Journal:  Cureus       Date:  2021-05-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.